Chief Medical Officer Provides Overview of
Preclinical Data Recently Presented at the 2023 American
Association of Cancer Research (AACR) annual meeting
Video Highlights Validation of the
ONCOPREX® Nanoparticle
Delivery System with a Second Tumor Suppressor Gene
AUSTIN,
Texas, May 23, 2023 /PRNewswire/ -- Genprex,
Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage
gene therapy company focused on developing life-changing therapies
for patients with cancer and diabetes, today released a new video
where the company's Chief Medical Officer, Mark Berger, MD, discusses the recently
presented positive preclinical data for the NPRL2 gene by Genprex's
research collaborators. The data were presented at the 2023
American Association of Cancer Research (AACR) annual meeting.
Click Here to Watch the Video.
The studies used the Company's non-viral ONCOPREX® Nanoparticle Delivery System in
KRAS/STK11 mutant anti-PD1 resistant metastatic human non-small
cell lung cancer (NSCLC) humanized mouse models. These positive
data support the therapeutic potential of the Company's non-viral
delivery system, which is being used in its current
REQORSA® clinical
oncology programs. REQORSA immunogene therapy is the Company's lead
drug candidate for lung cancer. The preclinical data also provide
further evidence that the ONCOPREX Nanoparticle Delivery System has
the ability to be successful using tumor suppressor genes other
than the TUSC2 gene that is already in use in clinical trials with
REQORSA. Lastly, the data suggest that targeting NSCLC with the
NPRL2 gene, potentially in combination with anti-PD1 treatment as
well, may provide therapeutic potential for lung cancer patients
progressing on anti-PD1 treatment.
"The study utilized the same delivery platform that Genprex uses
with our REQORSA product candidate but with a different tumor
suppressor gene," said Mark Berger,
MD, Chief Medical Officer at Genprex. "The whole point of our
oncology program is to identify tumor suppressor genes, which are
systematically deleted during cancer development, and then
re-express the tumor suppressor genes in cancers. This process has
shown preclinically that it can achieve strong efficacy and is
currently being evaluated in Phase 1/2 clinical trials of REQORSA.
Now researchers have replicated that process in in vitro
studies with the NPRL2 gene, which we believe is validation that
ONCOPREX as a platform may be used with multiple tumor suppressor
genes to address multiple types of cancer."
The abstract entitled, "NPRL2 gene therapy induces effective
antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant
metastatic human non-small cell lung cancer (NSCLC) in a humanized
mouse model," has been made available on Genprex's website
here.
To watch the video, please visit Genprex's website at
https://www.genprex.com/videos/.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage
gene therapy company focused on developing life-changing therapies
for patients with cancer and diabetes. Genprex's technologies are
designed to administer disease-fighting genes to provide new
therapies for large patient populations with cancer and diabetes
who currently have limited treatment options. Genprex works with
world-class institutions and collaborators to develop drug
candidates to further its pipeline of gene therapies in order to
provide novel treatment approaches. Genprex's oncology program
utilizes its proprietary, non-viral ONCOPREX® Nanoparticle Delivery System which
encapsulates the gene-expressing plasmids using lipid
nanoparticles. The resultant product is administered intravenously,
where it is taken up by tumor cells that then express tumor
suppressor proteins that were deficient in the tumor.The Company's
lead product candidate, REQORSA® (quaratusugene ozeplasmid), is being
evaluated in three clinical trials as a treatment for non-small
cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Both
NSCLC clinical programs received a Fast Track Designation from the
Food and Drug Administration. Genprex's diabetes gene therapy
approach is comprised of a novel infusion process that uses an
adeno-associated virus (AAV) vector to deliver Pdx1 and MafA genes
directly to the pancreas. In models of Type 1 diabetes, GPX-002
transforms alpha cells in the pancreas into functional beta-like
cells, which can produce insulin but are distinct enough from beta
cells to evade the body's immune system. In a similar approach,
GPX-003 for Type 2 diabetes, where autoimmunity is not at play, is
believed to rejuvenate and replenish exhausted beta cells.
Interested investors and shareholders are encouraged to sign up
for press releases and industry updates by visiting the Company
Website, registering for Email Alerts and by following Genprex on
Twitter, Facebook and LinkedIn.
Cautionary Language Concerning Forward-Looking
Statements
Statements contained in this press release
regarding matters that are not historical facts are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are made on the basis of the current beliefs,
expectations and assumptions of management, are not guarantees of
performance and are subject to significant risks and uncertainty.
These forward-looking statements should, therefore, be considered
in light of various important factors, including those set forth in
Genprex's reports that it files from time to time with the
Securities and Exchange Commission and which you should review,
including those statements under "Item 1A – Risk Factors" in
Genprex's Annual Report on Form 10-K for the year ended
December 31, 2022.
Because forward-looking statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding:
Genprex's ability to advance the clinical development,
manufacturing and commercialization of its product candidates in
accordance with projected timelines; the timing and success of
Genprex's clinical trials and regulatory approvals; the effect of
Genprex's product candidates, alone and in combination with other
therapies, on cancer and diabetes; Genprex's future growth and
financial status, including Genprex's ability to continue to
obtain capital to meet its long-term liquidity needs on acceptable
terms, or at all; Genprex's commercial and strategic partnerships,
including those with its third party vendors, suppliers and
manufacturers and their ability to successfully perform and scale
up the manufacture of its product candidates; and Genprex's
intellectual property and licenses.
These forward-looking statements should not be relied upon as
predictions of future events and Genprex cannot assure you that the
events or circumstances discussed or reflected in these statements
will be achieved or will occur. If such forward-looking statements
prove to be inaccurate, the inaccuracy may be material. You should
not regard these statements as a representation or warranty by
Genprex or any other person that Genprex will achieve its
objectives and plans in any specified timeframe, or at all. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
Genprex disclaims any obligation to publicly update or release any
revisions to these forward-looking statements, whether as a result
of new information, future events or otherwise, after the date of
this press release or to reflect the occurrence of unanticipated
events, except as required by law.
Genprex, Inc.
(877) 774-GNPX (4679)
GNPX Investor Relations
investors@genprex.com
GNPX Media Contact
Kalyn
Dabbs
media@genprex.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/genprex-unveils-new-video-featuring-chief-medical-officer-discussing-positive-preclinical-data-with-nprl2-gene-therapy-utilizing-non-viral-oncoprex-nanoparticle-delivery-system-301831751.html
SOURCE Genprex, Inc.